Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edwards Lifesciences (EW) PT Raised to $135 at Oppenheimer
December 9, 2021 6:31 AM ESTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $122.00) while maintaining an Outperform rating following the company's Analyst Day.
The analyst commented, "Edwards hosted its annual analyst day yesterday (12/8). Investors focused on developments in TMTT, especially... More
Edwards Lifesciences (EW) PT Raised to $132 at Stifel Following Analyst Day
December 9, 2021 6:12 AM ESTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $132.00 (from $129.00) while maintaining a Buy rating following the company's Analyst Day which underscores the key pipeline opportunities driving top-tier growth outlook for next year and beyond.
The analyst commented,... More
Edwards Lifesciences (EW) PT Raised to $140 at Cowen; Named Best 2022 Idea
December 9, 2021 5:49 AM ESTCowen analyst Joshua Jennings raised the price target on Edwards Lifesciences (NYSE: EW) to $140.00 (from $125.00) while maintaining an Outperform rating and named the stock a Best Idea for 2022.
The analyst commented, "EW's investor day featured favorable business updates, a reiteration of '21 guidance... More
